Abstracts tagged "anakinra and treatment"

Abstract Number: 1240 • 2014 ACR/ARHP Annual Meeting
Efficacy of Anakinra in Refractory Adult-Onset Still´s Disease: Multicenter Study of 41 Patients
Leyre Riancho-Zarrabeitia¹, Ricardo Blanco¹, Alejandro Olivé², Anne Riveros-Frutos², Santos Castañeda³, Maria Luisa Velloso Feijoo⁴, Javier Narváez⁵, Inmaculada Jiménez-Moleón⁶, Olga Maiz-Alonso⁷, Maria Carmen Ordóñez⁸, José Antonio Bernal⁹, M. Victoria Hernández¹⁰, Alberto Sifuentes Giraldo¹¹, Catalina Gomez Arango¹², Eva Galindez-Agirregoikoa¹², Vera Ortiz-Santamaría¹³, Jordi del Blanco¹⁴, Juan Ramón De Dios¹⁵, Mireia Moreno¹⁶, Jordi Fiter¹⁷, Marina de los Riscos¹⁸, Patricia Carreira¹⁸, María José Rodríguez Valls Sr.¹⁹, Francisco Ortiz-Sanjuán¹, Trinitario Pina Murcia²⁰, Montserrat Santos-Gómez¹ and Miguel A González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴H Valme, Sevilla, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Hospital San Cecilio, Granada, Spain, ⁷Rheumatology, HU Donostia, San Sebastián, Spain, ⁸Rheumatology, Hospital Regional Universitario Carlos Haya., Málaga, Spain, ⁹Rheumatology, HGU. Alicante., Alicante, Spain, ¹⁰Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ¹¹Rheumatology, HU Ramón y Cajal, Madrid, Spain, ¹²Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ¹³Rheumatology, Hospital General. Granollers., Granollers, Spain, ¹⁴Rheumatology, H Sant Jaume, Calella, Spain, ¹⁵Rheumatology, HU Álava, Vitoria, Spain, ¹⁶Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ¹⁷Rheumatology, HU Son Espases. Palma de Mallorca., Palma de Mallorca, Spain, ¹⁸Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁹Rheumatology, Rheumatolgy Unit. Hospital Jerez, Jerez, Spain, ²⁰Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain
Background/Purpose: Adult-onset Still's disease (AOSD) is frequently refractory to standard therapy. Anakinra (ANK), an interleukin-1 (IL-1) receptor antagonist, has demonstrated efficacy in single cases or…
Abstract Number: 1784 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of First Line Use Of Recombinant IL-1RA Treatment In Steroid naïve Systemic Juvenile Idiopathic Arthritis: Results Of a Prospective Cohort Study
S.J. Vastert¹, Wilco de Jager², Bo Jan Noordman², Dirk Holzinger³, Wietse Kuis⁴, Berent J. Prakken² and Nico M. Wulffraat⁵, ¹Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Institute of Immunology, University Muenster, Muenster, Germany, ⁴Pediatric immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵UMC Utrecht, Utrecht, Netherlands
Background/Purpose: To perform a prospective cohort study with recombinant IL-1RA (Anakinra, rIL-1RA) as first-line therapy in newly onset sJIA. Methods: Patients fulfilled the ILAR criteria…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].